Team

Dr. Jens Eckstein

Managing Partner

Jens has more than 18 years of biopharma venture capital and company creation experience and 10 years of operational experience in drug discovery and development. Before joining Apollo Health Ventures, Jens served as President of GlaxoSmithKline’s corporate venture fund SR One for eight years. During his tenure the SR One team invested over 500 million USD and was involved in 18 IPOs such as CRISPR Therapeutics, TP Therapeutics and Principia, as well as 12 M&A transactions. Jens is also co-founder and was Managing Director of GSK’s Action Potential Venture Capital (APVC) fund which invests in pioneering bioelectronic technologies. Previously, Jens was a General Partner at TVM Capital leading early-stage investments in Boston and CEO and President of SelectX Pharmaceuticals. At TVM Capital he was involved in building the first modern anti-aging biotech – Sirtris Pharmaceuticals. Jens is a Kauffman Fellow, a member of the EU-sponsored Gold Track Expert Council, and a passionate mentor for entrepreneurs and start-up teams in the area of innovative life science and healthcare IT. Before his investment career, Jens was leading research teams and pharma collaborations at Enanta Pharmaceuticals (NASDAQ: ENTA) and Mitotix.

LinkedInTwitter
Dr. Jens Eckstein